Medicortex Finland Oyj
Turku
About Medicortex Finland Oyj
Medicortex Finland is developing the first, non-invasive, point-of-care diagnostic test for Traumatic Brain Injury and concussion. Problem: A Traumatic Brain Injury (TBI) happens when an external force to the head causes damage to the brain tissue. Mild TBI, which is also known as concussion, is difficult to diagnose with current diagnostic methods such as CT and MRI scans. Solution: Medicortex is working towards the incorporation of brain injury biomarkers into a hand-held diagnostic kit, which will give a reliable result rapidly and will not require medical professionals to interpret the result. Business: We identified a unique biomarker that can be detected from urine and saliva. With strong clinical evidence and protected idea, we are willing to negotiate with bigger diagnostic companies for collaboration on manufacturing and distribution. Market: Customers include hospitals, emergency rooms, paramedics and first responders, military paramedics, sports teams (especially contact sports such as rugby, American football, ice hockey), schools, pharma and insurance companies. Accomplishments: We have completed three clinical trials which have demonstrated the ability of the proprietary biomarker to distinguish TBI patients from healthy controls. The company has received grant funding from US Department of Defense (twice), European Union and Finnish Government.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $4.0M
- Last round: Grant (Oct 2022)
- Website: medicortex.fi
- Phone: +358 (0) 400 488 817
Industries & Categories
Biotechnology, Clinical Trials, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/medicortex-finland-oyj-41700 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.